Oncothyreon’s PX-478 is effective in preclinical model of human lung cancer
Oncothyreon Inc. today announced the presentation of data demonstrating the effectiveness of PX-478 in a preclinical model of human lung cancer at the 8th Annual Targeted Therapies of the Treatment of Lung Cancer meeting of the International Association for the Study of Lung Cancer in Santa Monica, California. The data were presented on February 22, 2008, by Jorg J. Jacoby, Ph.D., Instructor, University of Texas M.D. Anderson Cancer Center, Houston. Oncothyreon’s PX-478 is a small molecule inhibitor of hypoxia inducible factor (HIF)-1 alpha currently in a Phase 1 trial in patients with advanced metastatic cancer and lymphoma.
This entry was posted on Monday, February 25th, 2008 at 9:14 am and is filed under Research, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.